Phase 1 Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

November 30, 2012

Study Completion Date

March 31, 2013

Conditions

Solid Tumors

Interventions

DRUG

Oprozomib

Oral administration of Oprozomib on Days 1-5 of a 14 day cycle

Trial Locations (3)

South Texas Accelerated Research Therapeutics, San Antonio

Oncology Research Associates, Scottsdale

Sarah Cannon Research Institute, Nashville